Implementation science to scale and sustain tobacco treatment leveraging point of care paradigm and health information technology
- Institution
- Washington University, MO
- Principal investigator
- Li-Shiun Chen
- Funding
- $1.6M
- Duration
- 2025–2027
Moonbase score
Still being scored
Abstract
We propose to evaluate scale-up and sustainment strategies to promote tobacco use treatment (TUT) in cancer survivors. In a landmark study of 28 cancer centers, we learned that scale-up success is a function of both implementation strategies and clinical context. Clinic selection of implementation strategies varies, and the same strategies do not yield consistent outcomes across variable contexts. We need a rigorous comparison of commonly used strategies, knowledge on how context (and context-strategy fit) impacts scale-up and sustainment, and how to enhance scale-up and sustainment with additional strategies. In the UG3 phase, we will leverage the Practical, Robust Implementation and Sustainability Model (PRISM), a context-based extension of the Reach, Effectiveness, Adoption, Implementation, Maintenance (RE-AIM) framework, to adapt/refine strategies, harmonize outcomes, and establish trial feasibility across a range of clinic settings. UG3 Phase: Aim 1: Engage clinics using multilevel PRISM to identify contextual needs, core functions, and forms of strategies to scale-up and sustain TUT in a common protocol for use in the UH3. Aim 2: Establish the feasibility of a multi-stage RCT by demonstrating fidelity of strategy components, harmonized outcome availability, and refined thresholds for the successful reach of TUT. Go/no-go Threshold: To proceed to the UH3 phase, we must achieve >80% strategy fidelity, >80% outcome availability, and >15% TUT reach (based on empirical C3I data). UH3 Phase: Using a Type 3 effectiveness-implementation hybrid design, we will test strategies in a 2-stage cluster-randomized SMART trial of 72 clinics across 4 regional hubs. Stage 1 is a 4-arm cluster RCT to assess scale-up strategies. In Stage 2, non-responder clinics will proceed to a 2-arm cluster RCT to compare scale enhancement strategies. Responder clinics will undergo a 2-arm cluster RCT to compare sustainment strategies. Aim 3: Assess the effect of scale-up strategies on TUT reach and effectiveness. We hypothesize that Referral to Specialist, Point of Care, and combination will result in higher reach and effectiveness, compared to usual care. In a sub-aim, we will evaluate scale enhancement in non-responder clinics and hypothesize Precision Implementation (PI)+Biological Precision Treatment (BPT) will result in higher TUT reach, compared to PI alone. Aim 4: Test the effect of sustainment strategies on the maintenance of strategy component delivery, TUT reach, and effectiveness. We hypothesize that a clinic data-driven facilitation strategy (Precision Facilitation) will result in higher maintenance outcomes than General Facilitation. Aim 5. Examine implementation outcomes and determinants associated with comparative strategies. This proposal will develop a contextually-informed algorithm for cancer clinics in selecting optimal implementation strategies for TUT and advance implementation science in refining the strategy-context fit and metrics to inform precision efforts to scale-up and sustain TUT for cancer survivors.
Research team
- Ross C BrownsonPI
- Li-Shiun ChenPI
- Alex Taylor RamseyPI
LOADING MOONBASE SCORE
Questions for Washington University
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Washington UniversityNot yet scored
A multilevel intervention to personalize and improve tobacco treatment in primary care
Li-Shiun Chen · $679K · 2022–2027
- NIH · Rissana, LlcNot yet scored
A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
Patricia A Cavazos-Rehg · $918K · 2022–2026
- NIH · Washington University69
Population genomics and new tools for the endgame of onchocerciasis elimination in Africa
Warwick Grant · $615K · 2019–2025